ESR1 and prostate cancer: The combination therapy of an estrogen receptor antagonist, tamoxifen with an anti-androgen bicalutamide, reduced gynecomastia and breast pain in prostate cancer patients receiving anti-androgen therapy in a multicenter trial [13].